Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 2/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.34 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18563077 | 0.93 | PDE7A (0.37) | HTR4EHMT2HRH3CHRM2CHRM4 | |
| SCHEMBL1179409 | 0.89 | CHRM2 (0.35) | HTR4EHMT2HRH3CHRM2CHRM4 | |
| SCHEMBL28621310 | 0.88 | ALDH1A1 (0.33) | HTR4EHMT2HRH3CHRM2CHRM4 | |
| SCHEMBL28621312 | 0.88 | ALDH1A1 (0.33) | HTR4EHMT2HRH3CHRM2CHRM4 | |
| SCHEMBL28632204 | 0.88 | ALDH1A1 (0.33) | HTR4EHMT2HRH3CHRM2CHRM4 | |
| SCHEMBL883727 | 0.84 | PDE7A (0.35) | PDE7A | |
| Trifluoroacetic Acid SCHEMBL21816626 | 0.84 | HTR4 (0.40) | HTR4HRH3PDE7A | |
| SCHEMBL11951490 | 0.83 | KDM1A (0.45) | — | |
| SCHEMBL14454163 | 0.83 | KDM1A (0.45) | — | |
| SCHEMBL13874716 | 0.83 | KDM1A (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3640248-B1 | AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) | 2023-08-23 | — | — | EP | disclosed |
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2022-06-07 | — | — | US | disclosed |
| WO-2021262483-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021222174-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021208963-A1 | BCL-2 INHIBITOR | BEIGENE, LTD. (KY) | 2021-10-21 | — | — | WO | disclosed |
| WO-2021110102-A1 | METHODS OF CANCER TREATMENT USING BCL-2 INHIBITOR | BEIGENE, LTD. (KY) | 2021-06-10 | — | — | WO | disclosed |
| WO-2020238785-A1 | METHYL- AND TRIFLUOROMETHYL-CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR | 正大天晴药业集团股份有限公司 | 2020-12-03 | — | — | WO | disclosed |
| US-20200087296-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2020-03-19 | — | — | US | disclosed |
| US-10329263-B2 | Disubstituted 1, 2, 4-triazine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-25 | — | — | US | disclosed |
| EP-3277682-B1 | 6-MORPHOLINYL-2-PYRAZOLYL-9H-PURINE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | DAIICHI SANKYO CO LTD (JP) | 2019-04-24 | — | — | EP | disclosed |
| WO-2015163427-A1 | NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND | 田辺三菱製薬株式会社 | 2015-10-29 | — | — | WO | disclosed |
| EP-2857388-A1 | Azoles containing sulfone | Grünenthal GmbH (DE) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013016999-A1 | HETEROARYL-PYRIMIDINE DERIVATIVES, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏豪森药业股份有限公司 (CN) | 2013-02-07 | — | — | WO | disclosed |
| US-7674788-B2 | 7-amino-6-chloro-2-piperazin-1-yl-4-pyrrolidin-1-yl-pteridine; central nervous system, respiratory, gastrointestinal or inflammatory diseases; joints, skin or eyes diseases; cancer; phosphodiesterase 4 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-09 | — | — | US | disclosed |
| US-7674788-B2 | 7-amino-6-chloro-2-piperazin-1-yl-4-pyrrolidin-1-yl-pteridine; central nervous system, respiratory, gastrointestinal or inflammatory diseases; joints, skin or eyes diseases; cancer; phosphodiesterase 4 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-09 | — | — | US | disclosed |
| US-20090093474-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | GRAUERT MATTHIAS | 2009-04-09 | — | — | US | disclosed |
| US-20070287704-A1 | 7-amino-6-chloro-2-piperazin-1-yl-4-pyrrolidin-1-yl-pteridine; central nervous system, respiratory, gastrointestinal or inflammatory diseases; joints, skin or eyes diseases; cancer; phosphodiesterase 4 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-13 | — | — | US | disclosed |
| US-20070287704-A1 | 7-amino-6-chloro-2-piperazin-1-yl-4-pyrrolidin-1-yl-pteridine; central nervous system, respiratory, gastrointestinal or inflammatory diseases; joints, skin or eyes diseases; cancer; phosphodiesterase 4 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-13 | — | — | US | disclosed |
| US-20070238718-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
| US-7241769-B2 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329263-B2 | Disubstituted 1, 2, 4-triazine compound | NR3C2, REN, NR5A1 | HTR4 4142/4885EHMT2 3516/4885HRH3 2590/4885 |
| US-20070287704-A1 | 7-amino-6-chloro-2-piperazin-1-yl-4-pyrrolidin-1-yl-pteridine; central nervous system, respiratory, gastrointestinal or inflammatory diseases; joints, skin or eyes diseases; cancer; phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE4C | HTR4 317/4885EHMT2 3100/4885HRH3 2129/4885 |
| US-20090093474-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | CYP3A43, CYP3A5, UGT1A3 | HTR4 848/4885EHMT2 3956/4885HRH3 387/4885 |
| US-20070238718-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | CYP3A43, CYP3A5, UGT1A3 | HTR4 848/4885EHMT2 3956/4885HRH3 387/4885 |
| US-20200087296-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, EGFR | HTR4 2537/4885EHMT2 4116/4885HRH3 3238/4885 |
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | WEE1, WEE2, EGFR | HTR4 2537/4885EHMT2 4116/4885HRH3 3238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.